Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Quick facts
Marketed products
- aMIL · Oncology
aMIL is a personalized neoantigen vaccine that trains the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations. - Contrave · Other
- Lupron · Other
- Rabbit antithymocyte globulin
- Taxotere · Oncology
- Xeloda · Oncology
Phase 3 pipeline
- Azacitadine · Other
- Cisplatin + Gemcitabine · Oncology
Cisplatin and gemcitabine work together as a chemotherapy combination to damage cancer cell DNA and inhibit nucleotide synthesis, leading to cell death.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins portfolio CI brief
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins pipeline updates RSS
Frequently asked questions about Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
What are Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins's marketed drugs?
Top marketed products include aMIL, Contrave, Lupron, Rabbit antithymocyte globulin, Taxotere, Xeloda.
What is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins's pipeline?
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins has 2 drugs in Phase 3, 0 in Phase 2, 2 in Phase 1. Late-stage candidates include Azacitadine, Cisplatin + Gemcitabine.
Related
- aMIL · Oncology
- Contrave · Other
- Lupron · Other
- Rabbit antithymocyte globulin
- Taxotere · Oncology
- Sector hub: All tracked pharma companies